Our Portfolio

Gatehouse Bio, Inc.

David Salzman, PhD | Massachusetts, United States

Gatehouse Bio, Inc.

David Salzman, PhD | Massachusetts, United States

Multi-class classifier for CNS Disorder type and Alzheimer’s Disease progression

The current lack of validated, FDA-approved biomarkers for the diagnosis of Alzheimer’s Disease, leaves the burden of diagnosing AD on tracking mental and cognitive decline. With dementias representing a complex and heterogeneous set of neurological disorders, the reality is that rates of misdiagnosis are high.

To address this, Gatehouse Bio has generated small RNA sequencing data from cerebrospinal fluid (CSF) of postmortem, neuropathologically verified patient samples from the Banner Health Institute and Netherlands Brain Bank. We analyzed the data using a biology influenced machine learning platform that classifies and subtypes diseases using regulatory genes called small RNAs (sRNA).

The sRNAnalytics platform utilizes an AI-powered, computational platform that analyzes the small RNA sequencing data to identify sRNA signatures that can be assessed as biomarkers for disease activity, or as predictive markers. Machine Learning classifiers will allow us to find unique biology indicative of neurons specifically affected by AD, and not other neurological disorders, or we can build classifiers that are trained towards other comorbidities. This data can be combined to generate a sequence-based test that identifies which diseases - and in which proportion - a patient has. These signatures can be further analyzed to help discern the molecular drivers behind a given disease and aid in the discovery of novel therapeutics that target molecular pathways of interest.

The creation of classifiers for AD and AD-related comorbidities will be an essential tool for anyone studying (and investing in) AD and other neurodegenerative diseases. Our small RNA classifiers can be utilized to select patients for clinical trials, and importantly can add vital neuropath information to publicly available data sets that researchers are using to study neurodegenerative diseases.